Epigenetics review of preeclampsia weighs therapeutic targets and barriers to clinical translation
Background: Connecting placental gene regulation to therapeutic research
A literature review examined epigenetic changes in preeclampsia as potential therapeutic targets. The authors synthesized pathways linking DNA methylation, histone regulation, non-coding RNAs, and extracellular vesicles to placental dysfunction and maternal vascular responses. The proposal is to use molecular signals to distinguish biological subtypes and identify possible future interventions; the review does not demonstrate the therapeutic efficacy or pregnancy safety of any new drug.
Preeclampsia involves abnormalities in placental development, an imbalance in angiogenesis, vascular endothelial dysfunction, and inflammation. Current management centers on close monitoring and blood-pressure control, seizure prevention when indicated, and delivery when maternal or fetal risks rise. The review starts from the limited treatment options for addressing placental dysfunction itself.
Epigenetic systems that regulate gene expression contribute to placental development. DNA methylation and histone modifications adjust gene activity, while non-coding RNAs, which do not encode proteins, participate in transcriptional and post-transcriptional regulation. However, longitudinal data remain insufficient to determine whether changes observed in the disease are causal or responses to placental stress.
Key findings: A literature synthesis of candidate pathways
The authors searched PubMed and Web of Science for basic, translational, and clinical studies, then synthesized the literature after assessment by two experts. They explain that they chose a narrative, mechanistic synthesis because methods, specimens, and outcome measures varied substantially. The work included neither analyses of their own tissue samples nor animal dosing experiments, and it was not a quantitative meta-analysis pooling treatment effect sizes.
The review discusses methylation changes in FLT1, ENG, HIF1A, and other genes involved in angiogenesis and hypoxia responses as clues for therapeutic exploration. Observing a methylation change in a particular gene does not mean that globally reducing DNA methylation would be appropriate. A central challenge in modulating DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) is achieving selectivity for specific pathways and placental tissue.
Among non-coding RNAs, the review highlights the microRNAs (miRNAs) miR-210, miR-155, and miR-34a. It links them, respectively, to hypoxia and mitochondrial dysfunction, inflammation and endothelial activation, and apoptosis-related pathways. Inhibiting pathologically elevated miRNAs or replenishing protective miRNAs whose levels have declined remains a research-stage approach. Because these molecules can regulate multiple genes at once, unintended effects also need evaluation.
Extracellular vesicles and nanocarriers are candidate platforms for delivering RNA or regulatory molecules to the placenta. The concept is to use the way placenta-derived vesicles transfer cargo between cells as a basis for therapeutic delivery. Before clinical use, researchers would need to assess distribution in the body, passage across the placenta and fetal accumulation, immune activation, and effects on development after birth.
Implications and outlook: Validate molecular subtypes and assess safety first
The first step proposed by the authors is to validate epigenetic signals as reproducible markers of molecular subtypes. Next, they suggest linking them to clinical outcomes such as early-onset disease, severe hypertension, and fetal growth restriction, then advancing pathways with biological support and acceptable safety into intervention studies. The limitations identified by the review include the lack of a clinically validated panel of multiple epigenetic markers and variation associated with specimens, sampling time, analytical methods, and maternal comorbidities.
Drug development faces stricter constraints. The review explains that the cytotoxicity and developmental risks of existing DNMT inhibitors such as 5-azacytidine and decitabine are barriers to their direct use during pregnancy. Nutritional modulation is also a candidate for supportive or preventive research, but clinical evidence is inconsistent and appropriate doses are uncertain. Since most candidate therapies remain at experimental or preclinical stages, external validation in diverse populations, maternal and fetal safety assessments, and long-term follow-up of children's development should precede decisions about clinical translation.
Source: Original review in the Journal of Medicine and Life, DOI: 10.25122/jml-2026-0058.
Preeclampsia is increasingly understood not only as a clinical syndrome of hypertension and organ dysfunction, but also as a disorder in which placental gene regulation, maternal vascular adaptation, and inflammatory signaling are shaped by abnormal epigenetic control. While several reviews have described epigenetic biomarkers in preeclampsia, the therapeutic implications of these mechanisms remain less clearly integrated. This review, therefore, focuses on the translational potential of epigenetic pathways as therapeutic entry points, with particular attention to DNA methylation, histone regulation, non-coding RNA networks, extracellular vesicle communication, and hypoxia-responsive placental signaling. Rather than treating these mechanisms solely as diagnostic signatures, the article evaluates how they may define molecular endotypes, identify pregnancies that could benefit from closer surveillance, and guide future interventions targeting upstream placental dysfunction. Potential strategies include selective modulation of DNMT and HDAC activity, microRNA inhibition or replacement, nutritional and environmental epigenetic optimization, placenta-oriented nanocarrier delivery, and pharmacogenomic stratification. The review also addresses the central barriers to translation, including tissue specificity, maternal-fetal safety, off-target epigenomic effects, ethical acceptability, long-term developmental consequences, and regulatory uncertainty. By reframing epigenetic alterations as actionable biological circuits rather than isolated biomarkers, this work provides a therapeutic and precision-medicine perspective on preeclampsia and outlines research priorities needed before epigenetic interventions can be responsibly evaluated in pregnancy.
This review offers criteria for connecting epigenetic signals to the selection of study populations in follow-up research and to safety assessments. For example, studies could repeatedly measure epigenetic signals in maternal blood alongside clinical risk factors and angiogenesis markers, then assess whether particular molecular subtypes are associated with disease course. If reproducibility and clinical utility are confirmed, the findings could help guide monitoring intensity or support participant selection for future intervention trials. Delivery-platform development would require studies assessing fetal exposure, immune activation, and postnatal development alongside the efficiency of delivery to the placenta. These are scenarios contingent on validation. The review alone does not establish a basis for recommending epigenetic drugs or nutritional supplements as preeclampsia treatment.